Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

ObjectiveCrizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib in advanced non-small-cell lung cancer (NSCLC) with concomitant ALK rearrangement and c-Met overexpression.MethodsTotally, 4622 advanced NSCLC patients from two institutes (3762 patients at the Guangdong Lung Cancer Institute from January 2011 to December 2016 and 860 cases at the Perking Cancer Hospital from January 2015 to December 2016) were screened for ALK rearrangement with any method of IHC, RACE-coupled PCR or FISH. C-Met expression was performed by IHC in ALK-rearranged patients, and more than 50% of cells with high staining were defined as c-Met overexpression. The efficacy of crizotinib was explored in the ALK-rearranged patients with or without c-Met overexpression.ResultsSixteen patients were identified with c-Met overexpression in 160 ALK-rearranged cases, with the incidence of 10.0% (16/160). A total of 116 ALK-rearranged patients received the treatment of crizotinib. Objective response rate (ORR) was 86.7% (13/15) in ALK-rearranged patients with c-Met overexpression and 59.4% (60/101)in those without c-Met overexpression, P = 0.041. Median PFS showed a trend of superiority in c-Met overexpression group (15.2 versus 11.0 months, P = 0.263). Median overall survival (OS) showed a significant difference for ALK-rearranged patients with c-Met overexpression group of 33.5 months with the hazard ratio (HR) of 3.2.ConclusionsC-Met overexpression co-exists with ALK rearrangement in a small population of advanced NSCLC. There may be a trend of favorable efficacy of crizotinib in such co-altered patients.

[1]  T. Nakagawa,et al.  Tumorigenesis and Neoplastic Progression Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer , 2012 .

[2]  T. Mok,et al.  Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation , 2014, Clinical Cancer Research.

[3]  Fan Tong,et al.  Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy , 2016, Journal of Hematology & Oncology.

[4]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[6]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Yi-long Wu,et al.  Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). , 2016 .

[8]  Yi-long Wu,et al.  Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression , 2010, Molecular Cancer.

[9]  G. Scagliotti,et al.  Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[11]  T. Mok,et al.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis , 2016, Clinical Cancer Research.

[12]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[13]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[14]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[15]  M. Saegusa,et al.  EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance , 2008, International journal of cancer.

[16]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. Kohno,et al.  c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[19]  M. Noguchi,et al.  Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. , 2012, Lung cancer.

[20]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[21]  Yi-long Wu,et al.  MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  W. Lam,et al.  MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors , 2009, International journal of cancer.

[23]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yi-long Wu,et al.  Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression. , 2015 .

[25]  M. Gaub,et al.  MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  R. Bende,et al.  The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma , 2003, Leukemia.

[27]  A. Shaw,et al.  Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). , 2012 .

[28]  K. O'Byrne,et al.  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Jie Cui,et al.  Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer , 2013, Journal of biomedical research.

[30]  Ying Cheng,et al.  [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version]. , 2013, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[31]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[32]  Y. Bang,et al.  Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. , 2012, Lung cancer.

[33]  I. Wistuba,et al.  Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit , 2014, Clinical Cancer Research.

[34]  Kari Chansky,et al.  The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  P. Ma,et al.  MET signaling: novel targeted inhibition and its clinical development in lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. O'Byrne,et al.  Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. , 2012, Clinical lung cancer.

[38]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[39]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[41]  Yi-long Wu,et al.  Targeting the MET pathway for potential treatment of NSCLC , 2015, Expert opinion on therapeutic targets.

[42]  Yi-long Wu,et al.  The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  W. Pao,et al.  EML4-ALK: honing in on a new target in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[45]  R. Tubbs,et al.  High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.